Trial Profile
Phase 2 Study of Oral Ezatiostat Hydrochloride (Telintra) in Patients With Lenalidomide (Revlimid) Refractory or Resistant, Low to Intermediate-1 Risk, Deletion 5q Myelodysplastic Syndrome.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 26 Nov 2013
Price :
$35
*
At a glance
- Drugs Ezatiostat (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- 01 Feb 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 22 Jan 2013 In order to focus its resources on the registrational programme, Telik has decided to stop further enrollment it its phase II exploratory trials, including this trial, as announced in a company media release.
- 22 Jan 2013 Status changed from recruiting to active, no longer recruiting based on information reported in a Telik media release.